Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 14Myeloid 8Sarcoma 1NET 1Lymphoid 1Endocrine 1Classical hematology 1CNS 1Breast 1

Conditions

Neurofibrosarcoma 1

Interventions

Doxorubicin 25Cyclophosphamide 24pembrolizumab 20Specimen Handling 19Temozolomide 16Magnetic Resonance Spectroscopy 15Surgical Procedures, Operative 14Radiotherapy 13Blood Specimen Collection 13Biopsy 13Gemcitabine 12fludarabine 11atezolizumab 11Vincristine 11Ifosfamide 11X-Rays 8Trabectedin 8Nivolumab 8Irinotecan 8Imatinib Mesylate 8Drug Therapy 8cabozantinib 7Surveys and Questionnaires 7Radiation 7liposomal doxorubicin 5abemaciclib 5Sunitinib 5Standard of Care 5Radiation Dose Hypofractionation 5Dactinomycin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × decitabine and cedazuridine drug combination × Sarcoma × Clear all
NCT04872543 2026-02-05

A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST)

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
25 enrolled
Sarcoma

Neurofibrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡